文献速递系统性红斑狼疮

监测羟氯喹血药浓度在系统性红斑狼疮中的临床意义:系统评价与荟萃分析

Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-03-30

该系统评价与荟萃分析纳入17项研究,评估SLE患者羟氯喹(HCQ)血药浓度与不依从性及SLEDAI评分的关系。低HCQ水平者报告不依从的比值比为2.95(95%CI 1.63,5.35,P<0.001);HCQ水平<500 ng/ml者SLEDAI评分高1.42分(95%CI 0.07,2.76,P=0.039);HCQ≥750 ng/ml者活动性疾病风险降低58%,SLEDAI评分低3.2分。

要点

  • 低HCQ血药浓度与报告不依从强烈相关(OR 2.95,95%CI 1.63,5.35)。
  • HCQ<500 ng/ml者SLEDAI评分高1.42分(95%CI 0.07,2.76)。
  • HCQ≥750 ng/ml者活动性疾病风险降低58%,SLEDAI低3.2分。

核心结论

  • 低HCQ血药浓度与报告不依从强烈相关,HCQ≥750 ng/ml可能是潜在治疗目标。

研究设计与样本

  • 系统评价与荟萃分析,检索并筛选604项研究,最终纳入17项观察性或干预性研究。

主要发现

  • 低HCQ水平者报告不依从的比值比为2.95(95%CI 1.63,5.35,P<0.001)。
  • 预设分析中,低于阈值HCQ水平组平均SLEDAI评分高3.14分(δ=3.14,95%CI -0.05,6.23,P=0.053)。
  • HCQ水平<500 ng/ml组SLEDAI评分高1.42分(δ=1.42,95%CI 0.07,2.76,P=0.039)。
  • 在1,223例患者中,HCQ≥750 ng/ml者活动性疾病风险降低58%,SLEDAI评分低3.2分。

关键数值与推荐

  • 低HCQ水平与报告不依从的OR为2.95(95%CI 1.63,5.35,P<0.001)。
  • HCQ<500 ng/ml与SLEDAI评分高1.42分相关(95%CI 0.07,2.76,P=0.039)。
  • HCQ≥750 ng/ml与活动性疾病风险降低58%及SLEDAI评分低3.2分相关。

临床怎么用

  • 监测HCQ血药浓度有助于区分不依从与HCQ疗效不足。
  • HCQ血药浓度≥750 ng/ml可作为潜在治疗目标参考。

局限性

  • 预设分析中低于阈值HCQ水平与SLEDAI评分差异的95%CI包含0(P=0.053)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Despite the pivotal role that hydroxychloroquine (HCQ) plays in treating systemic lupus erythematosus (SLE), less than 50% of patients take HCQ as prescribed. Measurement of HCQ blood levels can help clinicians distinguish nonadherence versus lack of efficacy of HCQ. Our objective was to systematically review publications and perform a meta-analysis to examine the correlation between HCQ levels and 1) nonadherence and 2) Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores, in SLE. METHODS: A comprehensive search was performed. We included observational and interventional studies that measured HCQ levels and assessed adherence or SLEDAI scores in adults with SLE. Forest plots compared pooled estimates of correlations between HCQ levels and reported nonadherence or SLEDAI scores. RESULTS: Among 604 studies screened, 17 were reviewed. We found 3-times higher odds of reported nonadherence in patients with low HCQ levels (odds ratio 2.95 [95% confidence interval (95% CI) 1.63, 5.35], P < 0.001). The mean SLEDAI score was 3.14 points higher in groups with below-threshold HCQ levels on a priori analysis (δ = 3.14 [95% CI -0.05, 6.23], P = 0.053), and 1.4 points higher in groups with HCQ levels of <500 ng/ml (δ = 1.42 [95% CI 0.07, 2.76], P = 0.039). Among 1,223 patients, those with HCQ levels ≥750 ng/ml had a 58% lower risk of active disease, and their SLEDAI score was 3.2 points lower. CONCLUSION: We found a strong association between low HCQ levels and reported nonadherence. Our results suggest that HCQ levels of ≥750 ng/ml might be a potential therapeutic target.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Garg S, Unnithan R, Hansen KE, et al. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2021. PMID: 32004406. doi:10.1002/acr.24155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。